Lead Product(s) : Sevelamer Hydrochloride
Therapeutic Area : Nephrology
Study Phase : Phase IV
Recipient : Medical University of Lodz
Deal Size : Inapplicable
Deal Type : Inapplicable
Different Effects of Non-calcium Phosphate Binders on Serum Calcium
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 01, 2018
Lead Product(s) : Sevelamer Hydrochloride
Therapeutic Area : Nephrology
Highest Development Status : Phase IV
Recipient : Medical University of Lodz
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : C1 Esterase Inhibitor, Human
Therapeutic Area : Nephrology
Study Phase : Phase I
Recipient : University of Wisconsin, Madison
Deal Size : Inapplicable
Deal Type : Inapplicable
CINRYZE as a Donor Pre-treatment Strategy in Kidney Recipients of KDPI>60%
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 06, 2015
Lead Product(s) : C1 Esterase Inhibitor, Human
Therapeutic Area : Nephrology
Highest Development Status : Phase I
Recipient : University of Wisconsin, Madison
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : NPSP795
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : National Institutes of Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
July 30, 2014
Lead Product(s) : NPSP795
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : National Institutes of Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SSP-004184
Therapeutic Area : Nephrology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 29, 2012
Lead Product(s) : SSP-004184
Therapeutic Area : Nephrology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lanthanum Carbonate
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 01, 2012
Lead Product(s) : Lanthanum Carbonate
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lanthanum Carbonate
Therapeutic Area : Nephrology
Study Phase : Phase III
Recipient : Salem Veterans Affairs Medical Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 20, 2011
Lead Product(s) : Lanthanum Carbonate
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Recipient : Salem Veterans Affairs Medical Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lanthanum Carbonate
Therapeutic Area : Nephrology
Study Phase : Phase III
Recipient : Bayer AG
Deal Size : Inapplicable
Deal Type : Inapplicable
Long-term Study in Chronic Kidney Disease (Extension From Study 14817)
Details : Undisclosed
Product Name : Fosrenol
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 24, 2010
Lead Product(s) : Lanthanum Carbonate
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Recipient : Bayer AG
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lanthanum Carbonate
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Effects of Lanthanum Carbonate on FGF-23 in Subjects With Stage 3 CKD
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 21, 2010
Lead Product(s) : Lanthanum Carbonate
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lanthanum Carbonate
Therapeutic Area : Nephrology
Study Phase : Phase III
Recipient : Bayer AG
Deal Size : Inapplicable
Deal Type : Inapplicable
Study in Chronic Kidney Disease (CKD) Not on Dialysis
Details : Undisclosed
Product Name : Fosrenol
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 26, 2010
Lead Product(s) : Lanthanum Carbonate
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Recipient : Bayer AG
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
